FDA sets panel review dates for analgesic Acurox and infantile spasms therapy Acthar
This article was originally published in Scrip
Executive Summary
The US FDA's anaesthetic and life support drugs advisory committee, in conjunction with the drug safety and risk management advisory committee, has scheduled a meeting for 22 April to review Acura Pharmaceuticals' investigational abuse-deterring analgesic, Acurox (oxycodone plus niacin). Acura's partner is King Pharmaceuticals.